Table 4.

Adverse Events on Dasatinib, Regardless of Causality, Present in at Least 5% of Patients or With at Least One Grade ≥ 3 Event

Adverse Event	All Patients (N = 62)				Once-Daily Schedule				Twice-Daily Schedule
	Any Grade		Grade 3 or 4		Any Grade		Grade 3 or 4		Any Grade		Grade 3 or 4
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Nonhematologic
Pain (joint, muscle)	46	74	4	6	24	39	2	3	22	35	2	3
Fatigue	45	73	4	6	22	35	4	6	23	37	0	0
Dyspnea	28	45	3	5	12	19	2	3	16	26	1	2
Neuropathy	19	31	3	5	10	16	1	2	9	15	2	3
Memory impairment	12	19	3	5	9	15	2	3	3	5	1	2
Headache	35	56	2	3	19	31	2	3	16	26	0	0
Cardiac	13	21	2	3	3	5	2	3	10	16	0	0
Skin toxicity	36	58	1	2	20	32	0	0	16	26	1	2
Diarrhea	33	53	1	2	15	24	1	2	18	29	0	0
Ocular/vision	20	32	1	2	13	21	1	2	7	11	0	0
Hyperglycemia	15	24	1	2	9	15	1	2	6	10	0	0
Mood alteration	15	24	1	2	11	18	0	0	5	8	1	2
Pleural effusion	8	13	1	2	2	3	1	2	6	10	0	0
Pruritus	5	8	1	2	3	5	0	0	2	3	1	2
Renal, genitourinary	5	8	1	2	3	5	1	2	2	3	0	0
Weight gain	4	6	1	2	1	2	0	0	3	5	1	2
Hypophosphatemia	4	6	1	2	2	3	0	0	2	3	1	2
Hyponatremia	3	5	1	2	1	2	0	0	2	3	1	2
Nausea	28	45	0	0	12	19	0	0	16	26	0	0
GI	23	37	0	0	10	16	0	0	13	21	0	0
Dizziness	22	35	0	0	11	18	0	0	11	18	0	0
Edema	20	32	0	0	11	18	0	0	9	15	0	0
Cough	16	26	0	0	8	13	0	0	8	13	0	0
Vomiting	13	21	0	0	7	11	0	0	6	10	0	0
Insomnia	13	21	0	0	9	15	0	0	4	6	0	0
Elevated ALT	10	16	0	0	4	6	0	0	6	10	0	0
Elevated AST	9	15	0	0	6	10	0	0	3	5	0	0
Alopecia	9	15	0	0	3	5	0	0	6	10	0	0
Allergy	8	13	0	0	6	10	0	0	2	3	0	0
Chills/rigors	7	11	0	0	3	5	0	0	4	6	0	0
Sweating	7	11	0	0	4	6	0	0	3	5	0	0
Hemorrhage	6	10	0	0	2	3	0	0	4	6	0	0
Hematologic
Neutropenia	39	63	13	21	19	31	8	13	20	32	5	8
Anemia	50	81	4	6	24	39	1	2	26	42	3	5
Thrombocytopenia	43	69	6	10	20	32	2	3	23	37	4	6